NCT Number: NCT02224768
YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey
To evaluate the effectiveness of the YERVOY® educational Risk Minimization (RM) tools in terms of awareness about these tools, their utilization, knowledge and comprehension of Immune Related Adverse Reaction (irAR)s, and appropriate behavior by Healthcare Professional (HCP)s and patients
Looking for future studies?
Notify MeKey information
Conditions
Age range
18 year and older
Sex eligibility
All sexes
Study type
Observational
Primary location
Local Institution, St Ives, Cambridgeshire, United Kingdom
About this study
A total sample size of 160 to 200 HCPs and 160 to 200 patients
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com
Inclusion criteria
- HCP experienced in the treatment of patients with the research compound and patients that have received at least one dose
Treatment and study plan
Primary outcomes
-
The proportion of YERVOY HCPs that are aware of the existence of the risk communications tools and how the tools were accessed (i.e. paper or electronic versions)
Time frame: 6 months
Distribution metrics and awareness of the tools from responses through the survey will be analysed and descriptive statistics will be used within the different participant groups
-
Questionnaire: "Who uses the RM communication tools, how, when they are used and how often they are used"
Time frame: 6 months
Web downloads metrics will be collected and the usage of tools from responses in the survey will be analysed, and descriptive statistics will be used within the participant groups
-
Level of knowledge and comprehension of the key elements of important identified risks associated with YERVOY treatment based on the scores obtained from the Questionnaire Surveys
Time frame: 6 months
Knowledge and comprehension in HCPs and patients, the knowledge surveys will provide the following data
- Total number of responses to the question including the proportions of correct answers to questions where appropriate
- Number or frequency and proportion of response options selected
- Percentage of responses/total responses per option
- Mean value and standard deviation (for appropriate questions)
From the obtained data, Acceptable levels of correct responses will be determined, post data analysis, reporting and discussion with EMA, to set baseline levels for potential future evaluations and then the scores will be assessed
-
HCP and patient behaviours via behavioural questions and scenarios based on the scores obtained from the Questionnaire Surveys
Time frame: 6 months
For determining appropriate behaviours in HCPs and patients, ideal expected behaviours will be mapped to the ideal care pathway from the Failure Modes and Effects Analysis (FMEA) as described in the RMP. The metrics will show:
- Total of number of participants answering the question.
- Proportions of participants providing correct answers (to identify knowledge and comprehension)
- Proportion of participants showing expected (ideal) behaviour - i.e. correct answers to individual questions.
- Proportion of participants showing non-ideal behaviour - i.e. partially correct or incorrect answers to individual questions.
Analysis will examine knowledge, comprehension and behaviours for different participant types (HCP, Hospital type and Country)
Sponsors and collaborators
Lead sponsor
Bristol-Myers Squibb
Industry
Registry information
Official study title
YERVOY Risk Minimisation Tool Evaluation Survey
Important dates
- Study start
- 2015
- Primary completion
- 2015
- Study completion
- 2015
- First posted
- Aug 25, 2014
- Registry last updated
- Dec 21, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC)
NCT04495257
Adenocarcinoma, Advanced Melanoma
New Haven, Connecticut, United States
View Trial DetailsA Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma
NCT04640545
Advanced Melanoma
Beijing, Beijing Municipality, China
View Trial DetailsPeripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
NCT05105100
Advanced Melanoma, Melanoma
San Francisco, California, United States
View Trial DetailsStudy of Trametinib + Ceritinib in Patients With Unresectable Melanoma
NCT03501368
Advanced Melanoma, Melanoma
Tampa, Florida, United States
View Trial Details